Tablet Form of Lynparza Approved in Japan as Maintenance Therapy for Recurrent Ovarian Cancer

Tablet Form of Lynparza Approved in Japan as Maintenance Therapy for Recurrent Ovarian Cancer
Japanese women with advanced ovarian cancer can now be treated with the new tablet formulation of Lynparza (olaparib) after a recent approval by the Japanese Ministry of Health, Labour and Welfare. The treatment was approved to delay disease progression in women who responded to a previous platinum-based chemotherapy regimen, regardless of their BRCA mutation status.

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *